Details:
Under the cooperation agreement, DKSH HK will provide full-agency services including key account management, marketing promotion, supply chain, and distribution for Bentrio (bentonite) Nasal Spray sales operation in Hong Kong and Macau.
Lead Product(s): Bentonite,Mono Propylene Glycol,Citric Acid
Therapeutic Area: Immunology Product Name: Bentrio
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Nuance Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 28, 2022
Details:
Myonal (eperisone hydrochloride) is a muscle-relaxant which is used to treat neck-shoulder-arm syndrome and Merislon is approved to treat vertigo and dizziness associated with inner-ear disorders.
Lead Product(s): Eperisone Hydrochloride
Therapeutic Area: Neurology Product Name: Myonal
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Eisai
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 07, 2022
Details:
The agreement will support both LEO Pharma’s strategy of building a simpler and more competitive organization and pipeline including its lead asset LP0133 (delgocitinib) and DKSH Business Unit Healthcare’s strategic focus of strengthening its regional footprint.
Lead Product(s): Delgocitinib
Therapeutic Area: Dermatology Product Name: LP0133
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Leo Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 29, 2022
Details:
The biosimilars planned under this agreement include biosimilar of Prolia® (denosumab, AVT03), Xgeva® (denosumab), Simponi® (golimumab), and Eylea® (aflibercept) as well as two undisclosed proposed biosimilars for immunology and oncology.
Lead Product(s): Denosumab
Therapeutic Area: Musculoskeletal Product Name: AVT03
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Lupin Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement September 07, 2022
Details:
Under the partnership, Alvotech Hf will be responsible for the development and supply of AVT02, while DKSH will oversee its registration and commercialization.
Lead Product(s): Adalimumab
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Recipient: Alvotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 24, 2020